Doc Lab Inc.

What Doc Lab Inc. does

Doc Lab Inc. is a privately held, vertically integrated manufacturer and service provider specializing in physician office laboratory (POL) solutions, headquartered in Hillsboro, Oregon. Founded in 2013, the company operates with a small, specialized team (~10 employees) of clinical laboratory scientists, regulatory specialists, field technicians, and business professionals, serving specialty medical practices across the United States—primarily urology, nephrology, OB/GYN, and multi-specialty groups. Doc Lab's core technology stack combines PCR-based molecular diagnostics (UTI Express™, UTI Max™, STI Panel, Vaginitis Panel) with automated spectrophotometric clinical chemistry (TrueUA® Quantitative Urinalysis). A defining differentiator is that the company formulates and manufactures its own reagents in-house, rather than reselling third-party chemistry, with technical support staffed by scientists who developed the assays.

The company's business model is a platform-plus-services structure: diagnostic tests and reagents are the primary revenue drivers, while an extensive service layer—end-to-end POL implementation, White Coat Lab Management (ongoing QC, compliance, and 24/7 support), regulatory consulting, FDA submission support, and MolDX guidance—secures long-term adoption. Pricing is custom and proposal-based with multi-year equipment contracts and monthly subscriptions for ongoing management, and the company reports a 30–45 day time-to-first-patient-test for new practices. Customer retention is reportedly near-perfect, with many clients staying over a decade, and clinical validation studies published in 2025 in peer-reviewed journals (Diagnostic Microbiology and Infectious Disease) provide efficacy evidence for the PCR testing platform. Geographic operations are US-only, with UTI Max currently restricted to non-MolDX states pending MolDX coverage anticipated in 2026.

Name

Doc Lab Inc.

Legal name

Doc Lab Inc.

Website

https://doclabinc.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Doc Lab Inc. is a privately held, vertically integrated manufacturer of PCR and clinical chemistry diagnostics, serving US physician office laboratories in urology, nephrology, OB/GYN, and multi-specialty practices with proprietary reagents and ongoing White Coat Lab Management services.

Ownership category

akta.pro rank

Product category

Physician Office Laboratory Services

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN)

Keywords

• Physician office laboratory
• Molecular diagnostics
• PCR testing services
• Clinical chemistry reagents
• Urinalysis systems

Headquarters

HQ city

Hillsboro

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Diagnostic Testing Products and POL Services: Revenue from sale of diagnostic tests, reagents, equipment placement, and ongoing POL management services including compliance monitoring, training, and technical support. Services provided under White Coat Lab Management ongoing partnership model.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Doc Lab Inc. manufactures proprietary diagnostic reagents and provides a portfolio of in-office molecular and chemistry tests (quantitative urinalysis, PCR-based UTI, STI, vaginitis, and prostate cancer risk panels) along with end-to-end physician office laboratory (POL) implementation services and ongoing White Coat Lab Management. The company's vertically integrated model bundles equipment, reagents, validation, regulatory compliance support, training, and 24/7 clinical/technical support to enable physician practices to operate compliant in-house labs with same-day diagnostic results.

Product overview

Doc Lab Inc. is a vertically integrated manufacturer and service provider for physician office laboratory (POL) solutions, offering a portfolio of diagnostic tests supported by comprehensive implementation and ongoing management services. The core product portfolio includes TrueUA® (quantitative urinalysis), UTI Express™ (routine PCR UTI testing), UTI Max™ (comprehensive molecular UTI testing for complex cases), MiCheck® Prostate (prostate cancer risk assessment), STI Panel PCR Testing, and Vaginitis Panel PCR Testing—all designed for in-office molecular and chemistry diagnostics. These products are complemented by Doc Lab Central™ reference laboratory services for send-out testing needs. The company differentiates through vertical integration, manufacturing its own reagents for quality control. Supporting services include end-to-end POL implementation, White Coat Lab Management (ongoing partnership), regulatory/compliance support, FDA consulting, MolDX guidance, training, equipment/supplies, billing guidance, and 24/7 clinical support. The offering operates as a platform-plus-services model where diagnostic tests are the revenue drivers and implementation/management services ensure successful adoption and long-term client retention.

Differentiator

Problem solved

Functional benefit

Brands

• TrueUA®: Quantitative urinalysis system delivering actual concentration measurements for sodium, potassium, and full UA panel.
• UTI Express™
• UTI Max™
• MiCheck® Prostate
• Doc Lab Central™
• White Coat Lab Management

Products and services

• TrueUA® Quantitative Urinalysis Automated quantitative urinalysis system delivering actual concentration measurements for sodium, potassium, and the full UA panel within minutes, replacing qualitative dipstick results with precise numerical values through spectrophotometric analysis. Designed for physician office laboratories.
• UTI Express™ PCR Testing PCR-based molecular UTI detection system providing same-day pathogen identification and antibiotic resistance gene detection, replacing traditional send-out cultures with faster, more accurate in-office results. Designed for physician office laboratories.
• UTI Max™ Comprehensive Molecular UTI Testing

Quantifiable outcome

• 88.08% clinical success rate vs 78.11% for traditional culture methods in complicated UTI testing (PCR-guided treatment)
• +4 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature7 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• MDxHealth: MDxHealth markets SelectMDx and other prostate cancer risk tests that compete directly with Doc Lab's MiCheck® Prostate offering in the urology practice channel.
• Pathnostics: Pathnostics specializes in molecular diagnostic testing for urology, including PCR-based UTI detection and antibiotic resistance profiling, making it a direct head-to-head competitor in Doc Lab's core urology POL channel.
• Acutis Diagnostics: Acutis Diagnostics is a specialty molecular diagnostics lab offering infectious disease PCR panels and clinical trial testing, serving physician practices in segments overlapping with Doc Lab's urology, OB/GYN, and primary care customers.
• Aegis Sciences Corporation: Aegis Sciences provides specialized clinical and forensic urine drug testing and infectious disease PCR panels, overlapping with Doc Lab's quantitative urinalysis and UTI PCR products in clinical practice channels.

Broad incumbents

• Quest Diagnostics: Quest Diagnostics operates a national clinical laboratory network with extensive molecular infectious disease, women's health, and urology testing menus, representing the largest incumbent competitor to Doc Lab's POL-based alternative.
• Labcorp (Laboratory Corporation of America): Labcorp is a national reference laboratory with a broad menu of clinical chemistry, molecular, and anatomic pathology services, including urology and women's health panels that overlap with Doc Lab's offering as an outsourced alternative to in-office testing.
• Sonic Healthcare USA: Sonic Healthcare USA operates a national network of clinical and anatomic pathology laboratories with broad molecular and chemistry menus that compete with Doc Lab's physician office offering as an outsourced alternative.
• OPKO Health (Bio-Reference Laboratories): OPKO Health's Bio-Reference Laboratories provides specialized molecular and clinical diagnostics, including urology-focused PCR testing, overlapping with Doc Lab's specialty POL offering.

Emerging players

• Caris Life Sciences: Caris provides molecular profiling and specialty diagnostics including prostate and cancer testing, with growing reach into urology practices that overlap with Doc Lab's MiCheck® and specialty POL segments.
• Exact Sciences: Exact Sciences is a molecular diagnostics company with cancer screening products (Cologuard, Oncotype) and growing urology presence, providing competitive overlap in molecular diagnostics for physician offices.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@doclabinc
• LinkedInlinkedin.com/company/usa-doc-lab

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Doc Lab Inc.